http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101194467-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-08 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P23-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-08 |
filingDate | 2008-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2012-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101194467-B1 |
titleOfInvention | Pyrrolidine Aryl-ether as NX3 Receptor Antagonist |
abstract | The present invention relates to a compound of formula (I) or a pharmaceutically active salt thereof comprising all stereoisomeric forms of the compounds of formula (I), individual diastereomers or enantiomers, or racemic and non-racemic mixtures thereof: (I) In this formula, Ar is aryl or 5- or 6-membered heteroaryl; Is a 6 to 9 membered mono or bi-heterocyclic group, wherein X is an additional hetero atom selected from the group consisting of carbon atoms, SO 2 , or N or O; If X is a carbon atom, O, SO 2 or unsubstituted N, R 1 is hydrogen, hydroxy, cyano,-(CH 2 ) q -OH,-(CH 2 ) q -NRR '-(CH 2 ) q -CN, lower alkyl, -S (O) 2 -lower alkyl, -NR-S (O) 2 -lower alkyl, -C (O) -lower alkyl, -NR-C (O) -lower alkyl, phenyl Or a heterocyclic group selected from piperidinyl-2-one; If X is an N-atom substituted by R 1 , then R 1 is hydrogen, — (CH 2 ) q —OH, — (CH 2 ) q —NRR ′, — (CH 2 ) q—CN, lower alkyl, — S (O) 2 -lower alkyl, aryl, 5- or 6-membered heteroaryl or -C (O) -lower alkyl, provided q is 2 or 3; R / R 'are independently of each other hydrogen or lower alkyl; R 2 is hydrogen, halogen, lower alkyl, cyano, lower alkoxy substituted with halogen, lower alkyl substituted with halogen, or 5- or 6-membered heteroaryl; R 3 is hydrogen or halogen; R < 4 > is hydrogen or lower alkyl; n is 1 or 2; when n is 2, R 1 may be the same or different; o is 1 or 2; when o is 2, R 2 may be the same or different; p is 1 or 2; when p is 2, R 3 may be the same or different; q is 1, 2 or 3; s is 0, 1, 2, 3 or 4. The compounds of the present invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety or attention deficit hyperactivity disorder (ADHD). |
priorityDate | 2007-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 391.